BALAXINSEBALAXI PHARMACEUTICALS LIMITEDMediumNeutral
Announced Wed, 25 Mar · 13:12 IST

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management

Management Changes View source PDF

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.9%1-day move
₹18.06
prior close
₹17.86
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.2-0.2-5.9-12.5+4.1+15.7+21.8+32.4+53.5+46.7+41.6+29.0
Up moveDown movePending
AI summary

Balaxi Pharmaceuticals has appointed Mr. Aman Purohit as the new Company Secretary and Compliance Officer with effect from March 25, 2026. The appointment was approved by the Board of Directors on the recommendation of the Nomination and Remuneration Committee at a meeting held the same day. Mr. Purohit is an Associate Member of ICSI with 6 years of post-qualification experience in secretarial compliance, having previously worked at Patil Rail Infrastructure and Re Sustainability IWM Solutions. This is a routine KMP-level change and does not involve any board-level or CFO/CEO changes.

Likely market impact

This is a routine managerial appointment with no material impact on the company's operations or shareholder value. Retail investors need not take any action; it simply fills a key compliance role required under the Companies Act.